0000000000942567

AUTHOR

Matteo Luciani

showing 6 related works from this author

Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management

2015

MaleAutoantibodies; Blood Coagulation Factor Inhibitors; Female; Humans; Male; Hemophilia A; Immunology and Allergy; HematologyBlood Coagulation Factor InhibitorsHumansImmunology and AllergyBlood Coagulation Factor InhibitorFemaleHematologyRecommendationHemophilia AAutoantibodieHumanAutoantibodies
researchProduct

Pain assessment and management in Italian Haemophilia Centres

2021

BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. The aim of this survey was to investigate the management and perception of pain among Italian physicians who treat PWH. MATERIALS AND METHODS: Between September and October 2017, a questionnaire was distributed to 35 Italian haemophilia treatment centres (60 physicians). RESULTS: Fifty-three haemophilia specialists completed the survey. We found that there was good agreement (98.1%) on the need to investigate pain at each clinical visit, but there was h…

Factor IXItalyHumansPain Managementpain heamophiliaHemophilia Ablood coagulation disorders haemophilia pain perception pain management surveysHaemostasis and ThrombosisPain Measurement
researchProduct

Fostering drug.storage,preparation and treatment modalities improves adherence to treatment with turoctocog-alfa in patients with haemophilia A:resul…

2019

Haemophilia Adrug storagetreatment adherence
researchProduct

Otogenic lateral sinus thrombosis in children: proposal of an experience-based treatment flowchart

2018

Purpose: To describe the prevalent clinical, laboratory, and radiological features of otogenic lateral sinus thrombosis (OLST) in children; to identify clinical predictors of outcome; to propose a management algorithm derived from experience. Methods: A retrospective review was conducted of the clinical records of patients with OLST, treated in a single tertiary care referral center for pediatric disease from 2006 to 2017. The inclusion criteria were pediatric age (0–16 years) and OLST diagnosis confirmed by a pre- and post-contrast CT or venography–MRI scan. Primary outcome measures were early (1–2 months) and late (6 months) sinus recanalization assessed by means of neuroimaging. Results:…

Pediatricsmedicine.medical_specialtyMastoiditismedicine.medical_treatmentMastoidectomyThrombophilia03 medical and health sciences0302 clinical medicineThrombophiliaMedicineProtein S deficiency030223 otorhinolaryngologyChildrenLateral Sinus ThrombosisPrognostic factorbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineRetrospective cohort studyGeneral Medicinemedicine.diseaseOtogenic lateral sinus thrombosiOtorhinolaryngologyOtorhinolaryngologyNeurosurgerybusiness030217 neurology & neurosurgeryEuropean Archives of Oto-Rhino-Laryngology
researchProduct

ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers

2021

AbstractConsidering the profound influence exerted by the ABO blood group system on hemostasis, mainly through the von Willebrand factor and factor VIII (FVIII) complex, we have conducted a study evaluating the possible role of blood type on the risk of inhibitor development in hemophilia A. A total of 287 consecutive Caucasian patients with severe hemophilia A (202 without FVIII inhibitors and 85 with FVIII inhibitors) followed at seven Italian Hemophilia Treatment Centers belonging to the Italian Association of Hemophilia Centers (AICE) were included in the study. A higher prevalence of O blood group was detected in patients without inhibitors as compared in inhibitor patients (55 vs. 30.…

Malecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHemophilia ASevere hemophilia AABO Blood-Group SystemVon Willebrand factorhemic and lymphatic diseasesInternal medicineABO blood group systemABO blood group; hemophilia; inhibitors; risk factorshemophiliainhibitorsHumansMedicinerisk factorsIn patientBlood typebiologybusiness.industryABO blood groupHematologyinhibitorItalyHemostasisbiology.proteinFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres

2022

Although synovitis is recognized as a marker of joint disease activity, its periodic assessment is not included in routine clinical surveillance of patients with haemophilia (PwH). In order to evaluate the current knowledge and to identify controversial issues, a preliminary literature search by the Musculoskeletal Committee of the Italian Association of Haemophilia Centres (AICE) has been conducted. Statements have been established and sent to the Italian AICE members to collect their level of agreement or disagreement by a Delphi process. Thirty-seven consensus recommendations have been drafted. We found a general agreement on the indication to consider the presence of synovitis as a mark…

haemophilia; haemophilic arthropathy; synovitis; Chronic Disease; Consensus; Hemophilia A; Humans; Italy; Synovitishaemophilia haemophilic arthropathy synovitisConsensusSynovitisItalyChronic Diseasehaemophilic arthropathyhaemophiliaHumansHematologyHemophilia ABritish Journal of Haematology
researchProduct